DUBLIN–(BUSINESS WIRE)–The “Peptide Therapeutics – Global Market Outlook (2019-2027)” report has been added to ResearchAndMarkets.com’s offering.
The Global Peptide Therapeutics market accounted for $28.15 billion in 2019 and is expected to reach $66.76 billion by 2027 growing at a CAGR of 11.4% during the forecast period.
Increasing prevalence of cancer, presence of strong product pipeline portfolio and an increasing number of cases of the metabolic disorder is driving market growth. However, stringent government regulation for the approval process is hampering the growth of the market.
Peptides represent one of a kind class of pharmaceutical compounds; it is recognized for being adequate and specific. Demand for peptides in clinical therapeutics is increasing as peptides have low production complexity as compared with that of protein-based biopharmaceuticals, which thereby reduces overall production cost.
Based on the type, the innovative segment is going to have high growth during the forecast period owing to the increasing investments by huge pharmaceuticals in R&D for the development of novel medicines and high prescription rate. By geography, Asia Pacific is going to have high growth during the forecast period owing to the vast patient pool, increasing healthcare expenditure and demand for newer advanced therapies.
Companies Mentioned
- Teva Pharmaceutical
- Bachem Holding AG
- Sanofi
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- Lonza Inc.
- GlaxoSmithKline (GSK)
- Eli Lilly and Company
- Bristol-Myers Squibb(BMS)
- Merck & Co.
- AstraZeneca PLC
- Novo Nordisk A/S
- Ipsen
- Takeda Pharmaceutical Company Limited
What the report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2018, 2019, 2020, 2024 and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company Profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Key Topics Covered:
1 Executive Summary
2 Preface
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Peptide Therapeutics Market, By Type
5.1 Introduction
5.2 Innovative
5.3 Generic
5.4 Branded
6 Global Peptide Therapeutics Market, By Type of Manufacturers
6.1 Introduction
6.2 Outsourced
6.3 In-house
6.4 Contract Manufacturing Organizations (CMOs)
7 Global Peptide Therapeutics Market, By Route of Administration
7.1 Introduction
7.2 Pulmonary
7.3 Parenteral
7.4 Oral
7.5 Mucosal
7.6 Injection
7.7 Other Route of Administrations
7.7.1 Nasal
7.7.2 Intradermal
8 Global Peptide Therapeutics Market, By Synthesis Technology
8.1 Introduction
8.2 Solid Phase Peptide Synthesis (SPPS)
8.3 Liquid Phase Peptide Synthesis (LPPS)
8.4 Hybrid Technology
9 Global Peptide Therapeutics Market, By Type of Molecule
9.1 Introduction
9.2 Vasopressin
9.3 Somatostatin
9.4 Natriuretic
9.5 Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
9.6 Insulins
9.7 Immunopeptide
9.8 Glucagon and Analogs
9.9 Calcitonin
10 Global Peptide Therapeutics Market, By Application
10.1 Introduction
10.2 Cancer
10.2.1 Velcade (Bortezomib)
10.2.2 Zoladex (Goserelin)
10.2.3 Lupron/ Enantone/ Eligard (Leuprorelin)
10.3 Cardiovascular Disorder
10.3.1 Integrilin (Eptifibatide)
10.3.2 Angiomax (Bivalirudin)
10.4 Metabolic
10.4.1 Byetta (Exenatide)
10.4.2 Victoza (Liraglutide)
10.5 Respiratory
10.6 Gastro-Intestinal Infection (GIT)
10.6.1 Linzess (Linaclotide)
10.6.2 Gattex (Teduglutide)
10.7 Pain
10.8 Dermatology
10.9 Anti-infection
10.10 Central Nervous System
10.10.1 Copaxone (Glatiramer)
10.11 Renal
10.12 Infection
10.12.1 Victrelis (Boceprevir)
10.12.2 Incivek (Telaprevir)
10.13 Hematological Disorders
10.13.1 Kalbitor (Ecallantide)
10.13.2 Firazyr (Icatibant)
10.14 Acromegaly
10.15 Other Applications
10.15.1 Allergy/Immunological
10.15.2 Osteoporosis
11 Global Peptide Therapeutics Market, By End User
11.1 Introduction
11.2 Pharmaceutical and Biotechnology Industries
11.3 Hospitals
11.4 Contract Research Organization
11.5 Academic and Research Institutes
12 Global Peptide Therapeutics Market, By Geography
12.1 Introduction
12.2 North America
12.3 Europe
12.4 Asia Pacific
12.5 South America
12.6 Middle East & Africa
13 Key Developments
13.1 Agreements, Partnerships, Collaborations and Joint Ventures
13.2 Acquisitions & Mergers
13.3 New Product Launch
13.4 Expansions
13.5 Other Key Strategies
14 Company Profiling
For more information about this report visit https://www.researchandmarkets.com/r/w4f82s
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900